Rockwell Medical, Inc. (NASDAQ: RMTI)

Rockwell Medical, Inc. develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The company is a key supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. Hemodialysis is the most common form of end-stage kidney disease treatment, typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. This represents a large market opportunity for which Rockwell’s products are well-positioned to meet the needs of patients.

Rockwell generates revenue through the sale of its hemodialysis concentrates and related products. The company’s primary products include CitraPure, Dri-Sate, RenalPure, and SteriLyte, which are used to sustain a patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. These products are essential for dialysis clinics and hospitals, serving a critical customer base that includes all five of the leading dialysis providers in the United States, such as Fresenius and DaVita. The company also offers ancillary products like 5% acetic acid cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.

• CitraPure: This is a citric acid-based concentrate, packaged as a liquid acid concentrate in 55-gallon drums and one-gallon jugs sold in cases of four. It is also available as a dry powder acid concentrate to be used exclusively with Rockwell Medical's Dry Acid Concentrate Mixer. Each case of dry product produces 25 gallons of CitraPure liquid acid concentrate

• Dri-Sate: This is an acetic acid-based product packaged as a dry powder acetic acid concentrate to be used exclusively with Rockwell Medical's Dry Acid Concentrate Mixer. Each case of Dri-Sate dry product produces 25 gallons of RenalPure liquid acetic acid concentrate

• RenalPure: This includes both acid and bicarbonate concentrates. The acid concentrate is an acetic acid-based product packaged as a liquid acid concentrate in 55-gallon drums and one-gallon jugs sold in cases of two and four. The bicarbonate concentrate is a dry powder mixed on-site at the clinic and is packaged in bulk and individual treatment sizes

• SteriLyte: This is a liquid bicarbonate concentrate packaged in one-gallon jugs sold in cases of two and four, primarily used in acute care settings

• Bicarbonate Cartridges: These are single-use, premium grade bicarbonate cartridges containing sodium bicarbonate concentrate powder, packaged in either 720 grams or 900 grams disposable canisters. Each case contains ten cartridges

• Dry Acid Concentrate Mix System: This is a 510(k) approved system for exclusive use with Rockwell Medical's CitraPure and Dri-Sate dry acid products, enabling clinics to mix acid concentrate on-site. This system offers advantages such as lower cost per treatment, reduced storage space requirements, and more flexibility in scheduling deliveries

• Ancillary Products: These include essential supplies like 5% acetic acid cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers

Rockwell Medical holds a significant position in the hemodialysis concentrates market, being the leading supplier of liquid bicarbonate concentrates and one of the largest suppliers of acid and dry bicarbonate concentrates for dialysis patients in the United States. The company’s competitive advantages include a strong reputation for reliability, quality, and excellent customer service, as well as a core expertise in manufacturing and delivering hemodialysis concentrates. Key competitors include Fresenius Medical Care NA and Nipro Medical Corporation, both of which have substantial financial, technical, manufacturing, marketing, and research and development resources. However, Rockwell’s established customer base and longstanding reputation for quality and service provide a robust competitive edge.

Rockwell currently serves 294 customers, including all five of the leading dialysis providers in the United States, such as Fresenius and DaVita. The company’s customer mix is diverse, with most customer sales concentrations under 10%. However, DaVita accounted for 16% of Rockwell’s total net product sales in 2025 and 45% in 2024. Rockwell also supplies dialysis concentrates to distributors serving over 30 foreign countries, primarily in the Americas and the Pacific Rim. The company’s total international sales accounted for approximately 12% and 9% of its total sales in 2025 and 2024, respectively. Rockwell’s significant customers are important to its business, financial condition, and results of operations, and the loss of any significant accounts could have a material adverse effect on its operations.